New Antibiotic Gepotidacin Achieves Breakthrough Against Drug-Resistant Gonorrhea in Major Trial
Kieran Lockhart, May, 22 2025
Gepotidacin, a first-in-class oral antibiotic, has shown a 93% success rate against drug-resistant gonorrhea in a large phase 3 trial, rivalling existing treatments. Oral dosing could boost accessibility, while parallel discoveries target resistant strains. The WHO urges urgent action as resistant gonorrhea becomes harder to treat.
Categories:
Tags:
